Literature DB >> 12204702

The effect of latanoprost on intraocular pressure during 2 years of treatment.

Katarina Hedman1, Peter G Watson, Albert Alm.   

Abstract

Our objective was to study the intraocular pressure (IOP) in open-angle glaucoma or ocular hypertensive patients during long-term treatment with latanoprost. A total of 532 patients treated with 0.005% latanoprost were enrolled, including 493 and 113 patients treated for 6 and 24 months, respectively. Mean IOP was analyzed with the analysis of variance technique. The risk of treatment failure was analyzed with survival analysis technique. After 2 weeks of latanoprost treatment, the mean IOP was reduced 8.2 (32%) and 8.9 (34%) mm Hg in the subgroups of patients treated for 6 and 24 months, respectively. The change in mean IOP during 2 years of latanoprost treatment was not statistically significant (p = 0.15). Patients with primary open-angle glaucoma or ocular hypertension showed an 86% and 97% chance of receiving a sufficient IOP reduction with latanoprost (p < 0.01), repectively. The initial mean IOP reduction was maintained throughout the 2 years of treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12204702     DOI: 10.1016/s0039-6257(02)00301-6

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  13 in total

1.  Study of long term structural and functional changes in medically controlled glaucoma.

Authors:  Achyut N Pandey; S Sujata
Journal:  Int J Ophthalmol       Date:  2014-02-18       Impact factor: 1.779

2.  Efficacy of locally produced Latanoprost in the control of intraocular pressure in patients with primary open-angle glaucoma.

Authors:  Pir Salim Mahar; Nadeem H Butt; Syed Imtiaz Ali
Journal:  Int Ophthalmol       Date:  2017-12-05       Impact factor: 2.031

Review 3.  Pharmacologic management of glaucoma in childhood.

Authors:  Will Moore; Ken K Nischal
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

4.  The additive effects on intraocular pressure of combining nipradilol 0.25% and latanoprost 0.005% ophthalmic solutions: a prospective, randomized, multicenter study.

Authors:  Tadahiko Tsuru; Yoshiaki Kitazawa; Masahiko Usui; Satoki Ueno; Ikuo Azuma; Kanjiro Masuda
Journal:  Jpn J Ophthalmol       Date:  2008-11-11       Impact factor: 2.447

5.  Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.

Authors:  Anne J Lee; Peter McCluskey
Journal:  Clin Ophthalmol       Date:  2010-07-30

6.  Does the intraocular pressure-lowering effect of prostaglandin analogues continue over the long term?

Authors:  Caner Kara; Emine Malkoç Şen; Kadriye Ufuk Elgin; Kurtuluş Serdar; Pelin Yilmazbaş
Journal:  Int Ophthalmol       Date:  2016-08-09       Impact factor: 2.031

Review 7.  The medical and surgical treatment of glaucoma.

Authors:  Thomas S Dietlein; Manuel M Hermann; Jens F Jordan
Journal:  Dtsch Arztebl Int       Date:  2009-09-11       Impact factor: 5.594

8.  Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings.

Authors:  Robert N Weinreb; Jeffrey M Liebmann; Keith R Martin; Paul L Kaufman; Jason L Vittitow
Journal:  J Glaucoma       Date:  2018-01       Impact factor: 2.503

9.  Long-term cost and efficacy analysis of latanoprost versus timolol in glaucoma patients in Germany.

Authors:  Ulrich Thelen; Dietmar Schnober; Sonja Schölzel; Michael S Kristoffersen; Lindsay A Nelson; Jeanette A Stewart; William C Stewart
Journal:  Int J Ophthalmol       Date:  2013-04-18       Impact factor: 1.779

10.  Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma.

Authors:  Sıtkı Samet Ermiş
Journal:  Clin Ophthalmol       Date:  2012-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.